Business

Fake drugs: Karnataka cancels 16 licenses

By Sohail Khan 20 September 2026, 7:26 pm

Benchmarks
Nifty23,346.4075.81

FEATURED FUNDS★★★★★

Motilal Oswal Midcap Fund Direct-Growth

5Y Return
22 %

Invest Now

Enter search text:

Business News›News›India›Fake drugs: Karnataka cancels 16 licenses, suspends 8 including that of Pfizer depot

Read Today's Paper

Fake drugs: Karnataka cancels 16 licenses, suspends 8 including that of Pfizer depot
Synopsis

Karnataka's FDA raided a farmhouse, seizing spurious drugs and machinery valued at Rs 5.05 crore. The operation allegedly repackaged and relabeled low-cost medicines as expensive life-saving drugs. Licenses for sixteen entities were cancelled, and eight others were suspended by the department. This action follows a series of raids ordered by the new Health Minister UT Khader. Consumers are advised to purchase medicines only from licensed pharmacies and report suspicious packaging.

Centre introduces stricter penalties for fake data in drug applications — Fake drugs: Karnataka cancels 16 licenses, suspends 8 including that of Pfizer depot

Karnataka’s Food Safety and Drug Administration (FDA) has uncovered an alleged unlicensed pharmaceutical repacking and relabelling operation at a farmhouse in Bidadi, with spurious drugs, machinery and printing material worth about Rs 5.05 crore seized during a raid on August 18.

The department, which is conducting a series of raids on orders from new Health & Family Welfare Minister UT Khader, has also initiated action against retailers and wholesalers allegedly linked to the distribution and sale of spurious drugs. The licences of 16 entities have been cancelled and those of eight others suspended, according to an FDA statement.

The licence of Pfizer C&F Depot at Kempalinganahalli in Nelamangala taluk, Bengaluru Rural district, also figures among the licenses suspended.

The FDA's Drug Enforcement Wing conducted the joint inspection following a tip-off at a farmhouse in Kurubarakeranahalli in Bengaluru South district.

Preliminary findings suggest the premises were allegedly used to procure low-cost medicines from neighbouring states, repackage them and relabel them as expensive life-saving drugs. The products allegedly carried labels imitating imported products under the Pfizer brand.

The FDA said the counterfeit labels included QR and scanning codes that were non-functional when checked. The seized stock is undergoing laboratory analysis to establish its chemical composition, potency and sterility.

The operation has raised concerns over the risks posed by unlicensed drug repacking and counterfeit medicines, particularly when products are presented as branded or life-saving drugs. Under the Drugs and Cosmetics Act, 1940, a drug is spurious if it is an imitation or substitute for another drug, resembles another drug in a manner likely to deceive, or purports to be a manufacturer's product when it is not.

The department has registered a criminal case under the Act and is investigating the alleged supply chain. The seized drugs, machinery and printing material will be produced before the jurisdictional JMFC court for further proceedings, according to the FDA statement.

The FDA also found 30 boxes of expired medicines at the premises, raising concerns that expired products could have been reintroduced into the supply chain.

As part of the investigation, batch numbers and other details of the seized medicines are being blocked on the Karnataka FDA portal to prevent their further sale or distribution. Samples have been sent for testing.

The Drugs and Cosmetics Act provides stringent penalties for offences involving spurious drugs, with punishment depending on the nature of the offence and the relevant provision invoked.

The FDA has advised consumers to buy medicines only from licensed pharmacies and obtain valid invoices. It has also urged patients and consumers to report suspicious packaging, unusual labelling or non-functional QR codes to drug enforcement authorities.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(You can now subscribe to our WhatsApp channel)

Read More News on
pfizerfake drugsKarnataka FDAcounterfeit medicinesPfizer license suspensionspurious drugs

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year